The initial application of Anlotinib in liver transplantation patients of hepatocellular carcinoma beyond Milan criteria
Latest Information Update: 04 Dec 2020
At a glance
- Drugs Catequentinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2020 New trial record
- 17 Aug 2020 Recruitment is expected to begin on 01 Oct 2021 and recruitment completion is expected on 31 Oct 2022, according to Chinese Clinical Trial Register.